Natco Pharma Limited has informed the Exchange about FY26 Earnings Presentation
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Natco Pharma reported FY26 total revenue of INR 43,759 Mn, down from INR 47,840 Mn in FY25. EBITDA for FY26 stood at INR 17,341 Mn with margin of 39.6%, significantly lower than FY25's 53.3%. PAT for FY26 was INR 14,185 Mn versus INR 18,834 Mn in FY25, though Q4 PAT included a one-time tax benefit of INR 1,150 Mn from switching to the new tax regime. The company launched several products including Semaglutide Multi Dose Vials in India, Pomalidomide in the US, and completed the acquisition of a 35.75% stake in Adcock Ingram Holdings, South Africa. The US pipeline includes 28 Para IV products with over 20 potential first-to-file opportunities.
Revenue and margin contraction year-over-year signals competitive pressures in the pharma export business, though strategic launches and pipeline developments provide future growth visibility. The one-time tax benefit inflated Q4 PAT, masking underlying operational weakness.